
- /
- Supported exchanges
- / US
- / IRWD.NASDAQ
Ironwood Pharmaceuticals Inc (IRWD NASDAQ) stock market data APIs
Ironwood Pharmaceuticals Inc Financial Data Overview
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ironwood Pharmaceuticals Inc data using free add-ons & libraries
Get Ironwood Pharmaceuticals Inc Fundamental Data
Ironwood Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 351 M
- EBITDA: 97 728 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-13
- EPS/Forecast: 0.0775
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ironwood Pharmaceuticals Inc News

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first com...


Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval – – Company has engaged Goldman Sachs & Co. LLC to...

Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday?
We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) stands against other stock...

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
BOSTON, March 27, 2025--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the "Company") (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.